What AmbAgon Therapeutics does

AmbAgon Therapeutics is a preclinical-stage biopharmaceutical company developing molecular glue therapeutics that stabilize 14-3-3 protein-protein interactions to drug intrinsically disordered proteins historically considered undruggable. Founded in 2021 by Christian Ottmann (CEO, Eindhoven University of Technology), Michelle Arkin (UCSF), and Luc Brunsveld (TU/e), the company operates as AmbAgon Therapeutics B.V. headquartered in Eindhoven, Netherlands, with a US corporate entity (AmbAgon Therapeutics Inc., Delaware) supporting San Francisco-based activities. The 14-3-3 Molecular Glue Platform integrates three components: a structural 14-3-3 Encyclopedia of client binding motifs and protein structures, a privileged scaffold library spanning natural products, drug-like compounds, and molecular fragments, and a Drug Discovery Toolbox anchored by high-throughput X-ray crystallography combined with biochemical, biophysical, cellular, and pharmacodynamic assays.

The pipeline focuses on oncology and neurodegeneration with secondary metabolic disease applications, including a kinase-target program in lead optimization, a transcription factor/structural-protein oncology program in hit exploration, and a Parkinson's disease program developing 14-3-3:LRRK2 stabilizers in collaboration with the Michael J. Fox Foundation. A 2026 research collaboration with Symeres extends the platform into colorectal cancer molecular glues. The company has raised approximately $97 million cumulatively, anchored by an $85 million Series A in January 2022 led by Nextech Invest with participation from MRL Ventures Fund, Mission Bay Capital, Inkef Capital, DROIA Ventures, RA Capital, AbbVie Ventures, and Surveyor Capital, followed by smaller exempt offerings in 2025.

AmbAgon is pre-revenue with no commercial products or licensing agreements disclosed. The stated future revenue model relies on licensing deals, co-development partnerships with large pharmaceutical companies, and eventual product sales upon regulatory approval. The go-to-market motion is enterprise field sales targeting pharma partners for late-stage development and commercialization, while current distribution is limited to scientific publications, conference presentations, and academic collaborations.

Name

AmbAgon Therapeutics

Legal name

Ambagon Therapeutics B.V.

Website

https://ambagontx.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

AmbAgon Therapeutics is a preclinical biopharmaceutical company developing molecular glue therapeutics that stabilize 14-3-3 protein-protein interactions to target intrinsically disordered proteins in oncology, neurodegeneration, and metabolic diseases.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)

akta.pro secondary industry

Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream) (HLAAACAN)

Keywords

• Molecular glue therapeutics
• Drug discovery platform
• Protein-protein stabilizers
• Oncology drug development
• Neurodegeneration therapeutics

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Therapeutic Development and Licensing: Pre-revenue biotech company developing molecular glue therapeutics. Revenue will be generated through licensing deals, co-development partnerships, and eventual product sales upon regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Ambagon Therapeutics develops a proprietary 14-3-3 Molecular Glue Platform that leverages 14-3-3 adaptor proteins to stabilize protein-protein interactions, enabling small-molecule drug discovery against intrinsically disordered proteins previously considered undruggable. The company operates a pipeline of molecular glue candidates across oncology, neurodegeneration, and metabolic disease, with future commercialization planned through licensing deals and co-development partnerships with pharmaceutical companies.

Product overview

Ambagon Therapeutics is a biopharmaceutical company developing a proprietary 14-3-3 Molecular Glue Platform that enables the discovery and development of small molecule therapeutics targeting previously undruggable proteins. The platform consists of three integrated components: the 14-3-3 Encyclopedia (structural database), the 14-3-3 Privileged Scaffold Library (compound collection), and the Drug Discovery Toolbox (screening and assay technologies). These components work together to identify and optimize molecular glue compounds that stabilize 14-3-3:client protein interactions for therapeutic effect. The company's pipeline focuses on neurodegeneration and oncology applications, with programs in lead optimization and hit exploration stages.

Differentiator

Problem solved

Functional benefit

Products and services

• 14-3-3 Molecular Glue Platform A drug discovery platform leveraging 14-3-3 adaptor proteins to stabilize protein-protein interactions, enabling therapeutic modulation of previously undruggable targets. The platform integrates structural understanding of the 14-3-3:client interface, a dedicated privileged scaffold compound library, and high-throughput X-ray crystallography screening combined with biochemical, biophysical, cellular, pharmacodynamic and functional assays to power structure-enabled medicinal chemistry optimization.
• Molecular Glue Therapeutic Pipeline A pipeline of molecular glue therapeutic candidates targeting kinases, transcription factors, and other challenging proteins across oncology and neurodegeneration indications, including programs in lead optimization and hit-to-lead stages. The pipeline targets indications such as colorectal cancer and other solid tumors, Parkinson's disease, and metabolic disorders.

Quantifiable outcome

• 14-3-3 proteins interact with over 3,000 client proteins across the interactome
• +1 more outcomes

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Four partnerships are on record, tiered core.

• SymerescoreStrategic or Co-development Partner · 1 April 2026Research collaboration focused on molecular glue compounds for colorectal cancer. The project involves assessing compounds through in vitro and cellular assays and utilizing Symeres' synthesis and validation services to support preclinical development.
• Michael J. Fox Foundation for Parkinson's ResearchcoreStrategic or Co-development Partner · 8 April 2023Grant awarded to Ambagon and academic collaborators to study 14-3-3:LRRK2 stabilizers as a neuroprotective therapy for Parkinson's Disease.
• Eindhoven University of Technology (TU/e)coreStrategic or Co-development PartnerAcademic collaboration partner; Co-founder Christian Ottmann is Associate Professor at TU/e. Research collaboration on 14-3-3 biology and molecular glue therapeutics.
• University of California, San Francisco (UCSF)coreStrategic or Co-development PartnerAcademic collaboration partner; Co-founder Michelle Arkin is Professor and Department Chair of Pharmaceutical Chemistry at UCSF.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Novartis: Operates internal molecular glue and protein degradation programs alongside a broad pharmaceutical portfolio. Relevant as a potential large-pharma partner, acquirer, and competitive incumbent in protein modulation across oncology and CNS indications.
• Pfizer: Major pharma with active protein degradation investments (including Arvinas partnership) and internal molecular glue programs. Comparable as a potential acquirer and as a benchmark for oncology and CNS deal economics that Ambagon may face.
• Plexxikon (Daiichi Sankyo): Now part of Daiichi Sankyo, Plexxikon pioneered structure-based and fragment-based drug discovery (vemurafenib, pexidartinib). Comparable in leveraging structural biology to drug challenging protein targets; Gideon Bollag (Plexxikon alumnus) is an Ambagon advisor.
• Bristol Myers Squibb: Owns the Celgene molecular glue legacy (thalidomide, lenalidomide, pomalidomide, iberdomide) and is the dominant incumbent in the molecular glue therapeutic space. While broad-spectrum, BMS sets competitive benchmarks, partnership dynamics, and acquisition multiples for molecular glue companies like Ambagon.

Direct peers

• Arvinas: Pioneer in PROTAC and molecular glue degrader technology with clinical assets in oncology. Directly comparable modality (heterobifunctional and glue-based protein degraders), shared pharma partnership model (Pfizer, Bayer, Genentech), and overlapping oncology pipeline strategy.
• C4 Therapeutics: Clinical-stage developer of degrader therapeutics (molecular glue degraders including DCAF15-based glues). Directly comparable modality, oncology focus, and platform-plus-pipeline approach with pharma partnerships (Roche, Biogen, Merck KGaA).
• Monte Rosa Therapeutics: Clinical-stage biotech developing molecular glue degraders (MGDs) for cancer and immune-mediated diseases. Closely comparable approach: structure-based discovery of cereblon-modulating glues to degrade disease-driving proteins, with similar target ambitions in undruggable oncology targets.
• Kymera Therapeutics: Clinical-stage biotech developing targeted protein degraders (molecular glue degraders) for oncology and immunology. Closely comparable mechanism (molecular glue-based protein modulation), similar target classes (transcription factors, kinases), and similar business model (platform-plus-pipeline with pharma partnership optionality).

Emerging players

• Photys Therapeutics: Early-stage biotech developing proximity-induced pharmacology, using molecular glues to induce protein-protein interactions. Closely comparable emerging platform approach targeting undruggable proteins via induced proximity, with overlapping investor profile (MRL Ventures).
• HotSpot Therapeutics: Emerging biotech developing allosteric modulators of protein function through targeted binding at hotspot sites. Adjacent platform play addressing traditionally undruggable proteins, with similar scientific advisory overlap (Geraldine Harriman, Ambagon advisor, is CSO at HotSpot).

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xtwitter.com/ambagontx
• LinkedInlinkedin.com/company/ambagon-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Funding overview

Funding rounds4 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AmbAgon Therapeutics